The authors suggested that gastric cancer patients with SBS3 might benefit from platinum therapy or PARP inhibitor treatment since this approach was beneficial in breast, ovarian, prostate, primary peritoneal, and pancreatic cancers with defective DSB repair due to BRCA1/2 mutations, HR mutations, or high genomic instability score [53]. Here, PARP1 is linked to gastric cancer.